
  
    
      
        Background_NNP
        Carcinoma_NNP of_IN cervix_NN uteri_NN (_( cervical_JJ cancer_NN ,_, CC_NNP )_) is_VBZ a_DT
        leading_VBG cause_NN of_IN cancer-related_JJ mortality_NN in_IN women_NNS
        worldwide_NN [_NN 1_CD 2_CD ]_NN ._. CC_NNP arises_VBZ by_IN distinct_JJ morphologic_JJ
        changes_NNS from_IN normal_JJ epithelium_NN and_CC progresses_VBZ to_TO carcinoma_NN
        through_IN a_DT series_NN of_IN well-defined_JJ preinvasive_JJ lesions_NNS ._.
        Histologically_NNP ,_, CC_NNP presents_VBZ as_IN either_DT squamous_JJ cell_NN
        carcinoma_NN (_( SCC_NNP )_) or_CC adenocarcinoma_NN (_( AC_NNP )_) [_NN 3_CD ]_NN with_IN SCC_NNP
        predominating_VBG ._. Converging_NNP evidence_NN from_IN epidemiological_JJ and_CC
        molecular_JJ studies_NNS suggests_VBZ that_DT infection_NN of_IN genital_JJ human_JJ
        papillomavirus_JJ (_( HPV_NNP )_) is_VBZ causally_RB linked_VBN to_TO the_DT development_NN
        of_IN CC_NNP [_NN 4_CD ]_NN ._. Since_IN only_RB a_DT small_JJ fraction_NN of_IN HPV-infected_NNP
        cervical_JJ intra-epithelial_JJ neoplastic_JJ (_( CIN_NNP )_) lesions_NNS progress_NN
        to_TO invasive_JJ cancer_NN ,_, these_DT studies_NNS further_JJ suggest_VBP that_IN in_IN
        addition_NN to_TO HPV_NNP ,_, other_JJ host_NN genetic_JJ factors_NNS play_VBP a_DT role_NN in_IN
        cervical_JJ carcinogenesis_NNS [_NN 5_CD ]_NN ._. A_DT number_NN of_IN molecular_JJ
        studies_NNS have_VBP identified_VBN genetic_JJ alterations_NNS in_IN these_DT two_CD
        histologic_JJ types_NNS of_IN CC_NNP and_CC at_IN various_JJ stages_NNS of_IN precursor_NN
        lesions_NNS [_NN 6_CD 7_CD 8_CD ]_NN ._. Despite_IN this_DT molecular_JJ
        characterization_NN ,_, the_DT genetic_JJ basis_NN of_IN CC_NNP initiation_NN and_CC
        progression_NN is_VBZ still_RB very_RB poorly_RB understood_VBN ._. Therefore_RB ,_,
        identification_NN of_IN the_DT underlying_VBG genetic_JJ changes_NNS may_MD
        provide_VB further_JJ insight_NN into_IN the_DT molecular_JJ basis_NN of_IN CC_NNP ._.
        Epigenetic_NNP hypermethylation_NN in_IN the_DT promoter_NN regions_NNS of_IN a_DT
        number_NN of_IN genes_NNS has_VBZ been_VBN recognized_VBN as_IN an_DT important_JJ change_NN
        in_IN the_DT development_NN of_IN human_JJ cancer_NN [_NN 9_CD ]_NN ._. A_DT growing_VBG number_NN
        of_IN cancer-related_JJ genes_NNS have_VBP been_VBN identified_VBN to_TO harbor_NN
        methylation_NN of_IN cytosine_NN residues_NNS in_IN CpG-rich_NNP promoter_NN
        sequences_NNS ._. The_DT pattern_NN of_IN such_JJ promoter_NN methylation_NN has_VBZ
        been_VBN noted_VBN to_TO be_VB non-random_JJ in_IN various_JJ tumor_NN types_NNS ,_, while_IN
        certain_JJ genes_NNS are_VBP commonly_RB methylated_JJ in_IN diverse_JJ tumor_NN
        types_NNS [_NN 10_CD 11_CD ]_NN ._. The_DT extent_NN of_IN aberrant_NN promoter_NN
        hypermethylation_NN and_CC its_PRP$ association_NN with_IN loss_NN of_IN gene_NN
        function_NN in_IN cancer_NN suggests_VBZ that_IN CpG_NNP island_NN methylation_NN is_VBZ
        an_DT important_JJ mechanism_NN in_IN inactivating_VBG tumor_NN suppressor_NN
        genes_NNS (_( TSGs_NNP )_) ._.
        The_DT role_NN of_IN epigenetic_JJ gene_NN inactivation_NN in_IN cervical_JJ
        tumorigenesis_NNS is_VBZ poorly_RB understood_VBN ._. A_DT few_JJ previously_RB
        published_VBN reports_NNS on_IN CC_NNP and_CC its_PRP$ precursor_NN lesions_NNS showed_VBD
        promoter_NN methylation_NN of_IN specific_JJ genes_NNS [_NN 12_CD 13_CD ]_NN ._. However_RB ,_,
        these_DT studies_NNS were_VBD limited_VBN by_IN the_DT small_JJ number_NN of_IN genes_NNS and_CC
        tumors_NNS examined_VBD ._. To_TO investigate_VB the_DT role_NN of_IN promoter_NN
        methylation_NN in_IN detail_NN in_IN cervical_JJ tumorigenesis_NNS ,_, we_PRP
        evaluated_VBD CpG_NNP methylation_NN of_IN 16_CD genes_NNS in_IN 90_CD CC_NNP specimens_NNS
        and_CC cell_NN lines_NNS ._. We_PRP found_VBD 86_CD ._. 6_CD %_NN of_IN CC_NNP patients_NNS exhibiting_VBG
        promoter_NN methylation_NN ._. The_DT 
        CDH_NNP 1_CD ,_, 
        DAPK_NNP ,_, 
        RARB_NNP ,_, and_CC 
        HIC_NNP 1_CD gene_NN promoters_NNS were_VBD frequently_RB
        methylated_JJ ._. Methylation_NNP status_NN was_VBD correlated_JJ with_IN clinical_JJ
        and_CC histologic_JJ characteristics_NNS ,_, and_CC microsatellite_NN
        instability_NN (_( MSI_NNP )_) ._. We_PRP also_RB found_VBD evidence_NN that_DT promoter_NN
        methylation_NN inactivates_NNS gene_NN expression_NN in_IN CC_NNP and_CC exposure_NN
        to_TO methylation_NN and_CC /_NN or_CC histone_NN deacetylase_NN (_( HDAC_NNP )_) -_: inhibiting_VBG
        agents_NNS reactivate_NN the_DT gene_NN expression_NN ._.
      
      
        Results_NNS
        
          CDH_NNP 1_CD ,_, DAPK_NNP ,_, RARB_NNP and_CC HIC_NNP 1_CD gene_NN promoters_NNS are_VBP
          frequently_RB methylated_JJ in_IN CC_NNP
          We_PRP examined_VBD the_DT status_NN of_IN promoter_NN hypermethylation_NN of_IN
          16_CD genes_NNS (_( 
          CDH_NNP 1_CD ,_, 
          DAPK_NNP ,_, 
          RARB_NNP ,_, 
          HIC_NNP 1_CD ,_, 
          FHIT_NNP ,_, 
          RASSF_NNP 1_CD A_DT ,_, 
          APC_NNP ,_, 
          CDKN_NNP 2_CD A_DT ,_, 
          MGMT_NNP ,_, 
          BRCA_NNP 1_CD ,_, 
          TP_NNP 73_CD ,_, 
          TIMP_NNP 3_CD ,_, 
          GSTP_NNP 1_CD ,_, 
          MLH_NNP 1_CD ,_, 
          p_NN 14_CD 
          ARF_NNP ,_, and_CC 
          RB_NNP 1_LS )_) in_IN eight_CD specimens_NNS of_IN normal_JJ
          cervical_JJ squamous_JJ epithelia_NN and_CC 90_CD CC_NNP specimens_NNS ._. Promoter_NNP
          hypermethylation_NN was_VBD not_RB found_VBN in_IN the_DT DNA_NNP isolated_VBD from_IN
          normal_JJ cervical_JJ smears_NNS for_IN any_DT of_IN the_DT tested_VBN genes_NNS ._.
          However_RB ,_, hypermethylation_NN was_VBD detected_VBN in_IN one_CD or_CC more_JJR
          genes_NNS in_IN 79_CD of_IN 90_CD (_( 87_CD ._. 8_CD %_NN )_) CC_NNP specimens_NNS ._. The_DT frequency_NN of_IN
          promoter_NN hypermethylation_NN for_IN individual_JJ genes_NNS was_VBD :_: 
          CDH_NNP 1_CD ,_, 51_CD ._. 1_LS %_NN ;_: 
          DAPK_NNP ,_, 43_CD ._. 3_LS %_NN ;_: 
          RARB_NNP ,_, 33_CD ._. 3_LS %_NN ;_: 
          HIC_NNP 1_CD ,_, 22_CD ._. 2_LS %_NN ;_: 
          FHIT_NNP ,_, 11_CD ._. 1_LS %_NN ;_: 
          RASSF_NNP 1_CD A_DT ,_, 10_CD %_NN ;_: 
          APC_NNP ,_, 10_CD %_NN ;_: 
          CDKN_NNP 2_CD A_DT ,_, 8_CD ._. 9_CD %_NN ;_: 
          MGMT_NNP ,_, 6_CD ._. 7_CD %_NN ;_: 
          BRCA_NNP 1_CD ,_, 5_CD ._. 6_CD %_NN ;_: 
          TP_NNP 73_CD ,_, 2_CD ._. 2_CD %_NN ;_: 
          TIMP_NNP 3_CD ,_, 1_CD ._. 1_CD %_NN ;_: 
          GSTP_NNP 1_CD ,_, 1_CD ._. 1_CD %_NN ;_: and_CC 
          MLH_NNP 1_CD ,_, 1_CD ._. 1_CD %_NN (_( Table_NNP 1_LS )_) ._. The_DT
          remaining_VBG two_CD genes_NNS (_( 
          p_NN 14_CD 
          ARF_NNP and_CC 
          RB_NNP 1_LS )_) did_VBD not_RB show_VB promoter_NN
          methylation_NN ._. Seventy-one_NNP of_IN 82_CD (_( 86_CD ._. 6_CD %_NN )_) primary_JJ tumors_NNS and_CC
          8_CD of_IN 8_CD (_( 100_CD %_NN )_) cell_NN lines_NNS exhibited_VBN methylation_NN ._. Although_IN
          the_DT patterns_NNS are_VBP similar_JJ ,_, primary_JJ tumors_NNS had_VBD a_DT higher_JJR
          frequency_NN of_IN methylation_NN of_IN 
          CDH_NNP 1_CD and_CC 
          DAPK_NNP genes_NNS as_IN compared_VBN to_TO cell_NN
          lines_NNS ,_, while_IN 
          RARB_NNP ,_, 
          HIC_NNP 1_CD ,_, 
          RASSF_NNP 1_CD A_DT ,_, 
          MGMT_NNP ,_, and_CC 
          TP_NNP 73_CD genes_NNS had_VBD higher_JJR prevalence_NN in_IN
          cell_NN lines_NNS as_IN compared_VBN to_TO primary_JJ tumors_NNS (_( Table_NNP 1_LS )_) ._. A_DT
          high_JJ frequency_NN of_IN promoter_NN methylation_NN was_VBD detected_VBN in_IN
          primary_JJ tumors_NNS for_IN 
          CDH_NNP 1_CD (_( 54_CD ._. 9_CD %_NN ;_: 45_CD of_IN 82_CD tumors_NNS )_) and_CC 
          DAPK_NNP (_( 45_CD ._. 1_LS %_NN ;_: 37_CD of_IN 82_CD tumors_NNS )_) ._. 
          RARB_NNP (_( 29_CD ._. 3_LS %_NN )_) and_CC 
          HIC_NNP 1_CD (_( 18_CD ._. 3_LS %_NN )_) genes_NNS were_VBD less_RBR
          frequently_RB methylated_JJ in_IN primary_JJ tumors_NNS ._. Other_JJ genes_NNS ,_, 
          FHIT_NNP (_( 11_CD %_NN )_) ,_, 
          APC_NNP (_( 11_CD %_NN )_) ,_, 
          CDKN_NNP 2_CD A_DT (_( 8_CD ._. 5_LS %_NN )_) ,_, 
          RASSF_NNP 1_CD A_DT (_( 7_CD ._. 3_LS %_NN )_) ,_, 
          BRCA_NNP 1_CD (_( 6_CD ._. 1_LS %_NN )_) ,_, 
          MGMT_NNP (_( 4_CD ._. 9_CD %_NN )_) ,_, and_CC 
          TIMP_NNP 3_CD (_( 1_CD ._. 2_LS %_NN )_) ,_, were_VBD rarely_RB
          methylated_JJ in_IN primary_JJ CC_NNP (_( Table_NNP 1_CD ,_, Fig_NNP ._. 1_LS )_) ._.
        
        
          Analyses_NNS of_IN HPV_NNP and_CC microsatellite_NN
          instability_NN
          Eighty-six_NNP of_IN 90_CD (_( 95_CD ._. 6_CD %_NN )_) tumors_NNS were_VBD positive_JJ for_IN HPV_NNP
          DNA_NNP ._. The_DT remaining_VBG four_CD tumors_NNS were_VBD HPV_NNP negative_NN ._. HPV_NNP 16_CD
          alone_RB or_CC in_IN combination_NN with_IN other_JJ HPV_NNP types_NNS was_VBD found_VBN in_IN
          55_CD (_( 61_CD ._. 1_LS %_NN )_) ._. HPV_NNP 18_CD was_VBD found_VBN in_IN eight_CD (_( 8_CD ._. 9_CD %_NN )_) tumors_NNS ,_,
          while_IN other_JJ HPV_NNP types_NNS (_( 20_CD different_JJ types_NNS )_) in_IN 23_CD (_( 25_CD ._. 6_CD %_NN )_)
          tumors_NNS ._.
          Of_IN the_DT 82_CD primary_JJ tumors_NNS studied_VBN for_IN promoter_NN
          methylation_NN ,_, 48_CD tumors_NNS were_VBD also_RB examined_VBN for_IN
          microsatellite_NN instability_NN (_( MSI_NNP )_) using_VBG 49_CD di-_NN or_CC
          tetra-nucleotide_JJ markers_NNS [_NN 14_CD 15_CD 16_CD 17_CD ]_NN ._. We_PRP found_VBD 9_CD of_IN
          48_CD (_( 18_CD ._. 8_CD %_NN )_) tumors_NNS had_VBD MSI-H_NNP ,_, and_CC 9_CD of_IN 48_CD (_( 18_CD ._. 8_CD %_NN )_) tumors_NNS
          exhibited_VBN MSI-L_NNP phenotype_NN ._. The_DT remaining_VBG tumors_NNS did_VBD not_RB
          show_VB MSI_NNP (_( Table_NNP 2_LS )_) ._.
        
        
          Promoter_NNP hypermethylation_NN in_IN relation_NN to_TO
          histological_JJ ,_, clinical_JJ and_CC genetic_JJ characteristics_NNS
          To_TO evaluate_VB the_DT relationship_NN between_IN promoter_NN
          hypermethylation_NN and_CC clinico-pathologic_JJ features_NNS ,_, as_RB well_RB
          as_IN other_JJ genetic_JJ changes_NNS ,_, methylation_NN status_NN was_VBD
          correlated_JJ with_IN histology_NN ,_, age_NN ,_, stage_NN and_CC size_NN of_IN the_DT
          tumor_NN ,_, clinical_JJ outcome_NN ,_, HPV_NNP type_NN ,_, and_CC microsatellite_NN
          instability_NN ._. Table_NNP 2_CD shows_VBZ the_DT results_NNS of_IN univariate_NN
          analyses_NNS examining_VBG the_DT associations_NNS between_IN methylation_NN
          and_CC these_DT characteristics_NNS ._. Although_IN both_DT squamous_JJ cell_NN
          carcinoma_NN (_( SCC_NNP ;_: 85_CD ._. 7_CD %_NN )_) and_CC adenocarcinoma_NN (_( AC_NNP ;_: 100_CD %_NN )_)
          exhibited_VBN an_DT overall_JJ high_JJ rate_NN of_IN promoter_NN methylation_NN ,_,
          we_PRP found_VBD statistically_RB significant_JJ differences_NNS in_IN various_JJ
          genes_NNS in_IN these_DT two_CD histologic_JJ subsets_NNS (_( Table_NNP 2_LS )_) ._. Promoter_NNP
          methylation_NN of_IN the_DT 
          CDH_NNP 1_CD ,_, 
          RARB_NNP ,_, 
          FHIT_NNP ,_, and_CC 
          MGMT_NNP genes_NNS was_VBD noted_VBN only_RB in_IN SCC_NNP ,_,
          whereas_IN the_DT AC_NNP exhibited_VBN significantly_RB higher_JJR frequency_NN
          of_IN promoter_NN methylation_NN of_IN 
          HIC_NNP 1_CD (_( 60_CD %_NN in_IN AC_NNP vs_NNS ._. 15_CD ._. 6_CD %_NN in_IN SCC_NNP )_) ,_, 
          APC_NNP (_( 80_CD %_NN in_IN AC_NNP vs_NNS ._. 6_CD ._. 5_CD %_NN in_IN SCC_NNP )_) ,_,
          and_CC 
          BRCA_NNP 1_CD (_( 40_CD %_NN in_IN AC_NNP vs_NNS ._. 3_CD ._. 9_CD %_NN in_IN SCC_NNP )_)
          (_( Table_NNP 2_LS )_) ._.
          A_DT significant_JJ correlation_NN was_VBD observed_VBN between_IN the_DT
          overall_JJ frequency_NN of_IN methylation_NN and_CC the_DT tumor_NN stage_NN (_( P_NN =_SYM
          0_CD ._. 001_CD )_) ._. Higher_JJR stage_NN (_( stages_NNS II-IV_NNP )_) tumors_NNS exhibited_VBN an_DT
          increased_VBN overall_JJ frequency_NN of_IN promoter_NN methylation_NN
          (_( Table_NNP 2_LS )_) ._. However_RB ,_, the_DT differences_NNS were_VBD not_RB
          statistically_RB significant_JJ when_WRB individual_JJ genes_NNS examined_VBD ._.
          On_IN the_DT other_JJ hand_NN ,_, 
          RASSF_NNP 1_CD A_DT methylation_NN was_VBD associated_VBN
          with_IN low-grade_JJ tumors_NNS (_( P_NN =_SYM 0_CD ._. 003_CD )_) ._. Tumor_NNP size_NN has_VBZ no_DT
          effect_NN on_IN the_DT overall_JJ frequency_NN of_IN methylation_NN ._. Age_NNP also_RB
          has_VBZ no_DT influence_NN on_IN overall_JJ frequency_NN of_IN promoter_NN
          methylation_NN ._. However_RB ,_, 
          RARB_NNP gene_NN was_VBD more_RBR frequently_RB
          methylated_JJ in_IN younger_JJR patients_NNS (_( 34_CD ._. 7_CD %_NN in_IN below_IN 50_CD years_NNS
          and_CC 21_CD ._. 2_LS %_NN in_IN above_IN 50_CD years_NNS age_VBP )_) (_( P_NN =_SYM 0_CD ._. 02_CD )_) ._. Promoter_NNP
          methylation_NN of_IN 
          APC_NNP (_( 2_CD ._. 0_CD %_NN in_IN patients_NNS below_IN 50_CD
          years_NNS vs_NNS ._. 24_CD ._. 2_LS %_NN in_IN patients_NNS above_IN 50_CD years_NNS age_VBP )_) (_( P_NN =_SYM
          0_CD ._. 001_CD )_) and_CC 
          BRCA_NNP 1_CD (_( 4_CD ._. 1_LS %_NN in_IN below_IN 50_CD years_NNS and_CC
          9_CD ._. 1_CD %_NN in_IN patients_NNS above_IN 50_CD years_NNS )_) (_( P_NN =_SYM 0_CD ._. 05_CD )_) genes_NNS were_VBD
          significantly_RB higher_JJR in_IN older_JJR patients_NNS ._.
          In_IN order_NN to_TO assess_VB the_DT prognostic_JJ role_NN ,_, we_PRP also_RB
          correlated_JJ treatment_NN response_NN and_CC clinical_JJ outcome_NN with_IN
          promoter_NN methylation_NN ._. The_DT overall_JJ frequency_NN of_IN
          methylation_NN was_VBD higher_JJR in_IN patients_NNS who_WP died_VBD of_IN cancer_NN
          (_( DOC_NNP )_) (_( 95_CD ._. 3_LS %_NN )_) as_IN compared_VBN to_TO those_DT who_WP were_VBD alive_JJ with_IN
          recurring_VBG disease_NN or_CC complete_JJ remission_NN (_( 76_CD ._. 9_CD %_NN )_) (_( Table_NNP 2_LS )_)
          (_( P_NN =_SYM 0_CD ._. 015_CD )_) ._. Although_IN statistically_RB not_RB significant_JJ ,_, all_PDT
          the_DT patients_NNS whose_WP$ tumors_NNS showed_VBD promoter_NN methylation_NN of_IN 
          MGMT_NNP (_( 4_CD tumors_NNS )_) and_CC 
          BRCA_NNP 1_CD (_( 5_CD tumors_NNS )_) genes_NNS DOC_NNP within_IN
          1_CD -_: 21_CD months_NNS of_IN follow-up_JJ after_IN the_DT initial_JJ diagnosis_NN ._.
          Promoter_NNP methylation_NN of_IN the_DT remaining_VBG genes_NNS did_VBD not_RB show_VB
          such_JJ differences_NNS in_IN relation_NN to_TO the_DT outcome_NN ._. To_TO assess_VB
          the_DT role_NN of_IN radiation_NN and_CC /_NN or_CC chemotherapy_NN treatment_NN on_IN
          outcome_NN ,_, we_PRP correlated_JJ methylation_NN with_IN response_NN in_IN
          patients_NNS with_IN at_IN least_JJS 5_CD months_NNS follow_VBP up_RB after_IN
          treatment_NN ._. No_DT significant_JJ differences_NNS in_IN the_DT overall_JJ
          promoter_NN methylation_NN were_VBD found_VBN in_IN patients_NNS with_IN complete_JJ
          remission_NN (_( CR_NNP )_) compared_VBN to_TO patients_NNS who_WP DOC_NNP or_CC had_VBD only_RB
          partial_JJ response_NN (_( PR_NNP )_) ._. In_IN this_DT group_NN ,_, all_PDT the_DT patients_NNS
          that_WDT showed_VBD methylation_NN of_IN 
          MGMT_NNP and_CC 
          BRCA_NNP 1_CD genes_NNS failed_VBD to_TO respond_VB to_TO
          the_DT treatment_NN suggesting_VBG promoter_NN methylation_NN of_IN these_DT
          genes_NNS may_MD be_VB a_DT bad_JJ prognostic_JJ indicator_NN (_( Table_NNP 2_LS )_) ._.
          Promoter_NNP methylation_NN of_IN 
          RARB_NNP gene_NN was_VBD also_RB predicted_VBN a_DT
          worse_JJR prognosis_NN as_IN 80_CD %_NN of_IN the_DT patients_NNS with_IN methylation_NN
          were_VBD either_CC DOC_NNP or_CC only_RB partial_JJ responders_NNS compared_VBN to_TO
          only_RB 20_CD %_NN patients_NNS with_IN CR_NNP exhibited_VBN methylation_NN of_IN this_DT
          gene_NN (_( Table_NNP 2_LS )_) ._.
          Table_NNP 3_CD summarizes_NNS the_DT results_NNS from_IN multivariate_NN Cox_NNP
          Survival_NNP models_NNS ._. Overall_RB ,_, after_IN adjusting_VBG for_IN age_NN ,_,
          treatment_NN ,_, tumor_NN size_NN ,_, stage_NN and_CC HPV_NNP type_NN ,_, neither_DT total_JJ
          number_NN of_IN methylated_JJ genes_NNS nor_CC presence_NN of_IN methylation_NN of_IN
          each_DT specific_JJ gene_NN were_VBD statistically_RB significantly_RB
          related_VBN to_TO survival_NN ._. However_RB ,_, methylation_NN of_IN 3_CD genes_NNS did_VBD
          suggest_VB a_DT doubling_VBG (_( 
          RASSF_NNP 1_CD A_DT and_CC 
          MGMT_NNP )_) or_CC tripling_VBG (_( 
          BRCA_NNP 1_LS )_) of_IN risk_NN compared_VBN to_TO those_DT
          who_WP did_VBD not_RB have_VB these_DT genes_NNS methylated_JJ ._. These_DT
          differences_NNS were_VBD not_RB statistically_RB significant_JJ due_NN to_TO
          small_JJ number_NN of_IN tumors_NNS analyzed_VBD and_CC need_VBP to_TO be_VB confirmed_VBN
          using_VBG a_DT larger_JJR sample_NN size_NN ._.
          Type_NNP of_IN HPV_NNP infection_NN had_VBD no_DT association_NN with_IN the_DT
          status_NN of_IN promoter_NN methylation_NN (_( Table_NNP 2_LS )_) ._. Although_IN the_DT
          MSI_NNP phenotype_NN also_RB had_VBD no_DT significant_JJ correlation_NN with_IN
          overall_JJ promoter_NN methylation_NN ,_, the_DT 
          HIC_NNP 1_CD (_( P_NN =_SYM 0_CD ._. 02_CD )_) and_CC 
          APC_NNP (_( P_NN =_SYM 0_CD ._. 08_CD )_) genes_NNS were_VBD
          frequently_RB methylated_JJ in_IN patients_NNS exhibiting_VBG MSI-H_NNP
          phenotype_NN (_( Table_NNP 2_LS )_) ._.
        
        
          CDH_NNP 1_CD and_CC RARB_NNP expression_NN in_IN CIN_NNP
          To_TO examine_VB the_DT role_NN of_IN 
          CDH_NNP 1_CD and_CC 
          RARB_NNP genes_NNS in_IN CC_NNP progression_NN ,_, we_PRP
          carried_VBD out_IN immunohistochemical_JJ analysis_NN in_IN 39_CD CIN_NNP
          specimens_NNS (_( Nine_CD low-grade_JJ and_CC 30_CD high-grade_JJ )_) ._. None_NN of_IN the_DT
          low-grade_JJ CINs_NNP showed_VBD down-regulated_JJ expression_NN ,_, while_IN
          only_RB 2_CD of_IN 30_CD (_( 6_CD ._. 7_CD %_NN )_) showed_VBD absent_JJ or_CC reduced_VBN expression_NN
          suggesting_VBG that_IN 
          CDH_NNP 1_CD inactivation_NN is_VBZ a_DT later_JJ event_NN
          in_IN CC_NNP development_NN ._. The_DT expression_NN pattern_NN of_IN RARB_NNP in_IN
          normal_JJ epithelium_NN is_VBZ complex_JJ since_IN the_DT staining_VBG
          intensities_NNS are_VBP highly_RB variable_JJ between_IN nuclear_JJ and_CC
          cytoplasmic_JJ compartments_NNS ._. There_EX was_VBD no_DT normal_JJ epithelium_NN
          to_TO evaluate_VB the_DT expression_NN in_IN most_JJS CIN_NNP cases_NNS studied_VBN ._.
          However_RB ,_, all_PDT the_DT cases_NNS that_IN we_PRP evaluated_VBD for_IN RARB_NNP
          immunoreactivity_NN showed_VBD some_DT positive_JJ mesenchymal_NN cells_NNS ._.
          We_PRP evaluated_VBD the_DT intensity_NN of_IN nuclear_JJ staining_VBG in_IN 34_CD
          cases_NNS of_IN paraffin-embedded_JJ tissues_NNS ._. One_CD (_( 11_CD ._. 1_LS %_NN )_) of_IN the_DT
          nine_CD low-grade_JJ CINs_NNP showed_VBD decreased_VBN nuclear_JJ expression_NN ,_,
          whereas_IN ,_, 15_CD (_( 60_CD %_NN )_) of_IN 25_CD evaluable_JJ high-grade_JJ CIN_NNP lesions_NNS
          showed_VBD complete_JJ lack_NN of_IN nuclear_JJ expression_NN (_( Fig_NNP ._. 2_LS )_) ._. If_IN
          confirmed_VBD ,_, the_DT down-regulated_JJ RARB_NNP expression_NN in_IN
          high-grade_JJ CINs_NNP suggests_VBZ that_IN this_DT occurs_VBZ early_RB in_IN
          progression_NN and_CC plays_VBZ a_DT role_NN in_IN the_DT development_NN of_IN
          CC_NNP ._.
        
        
          Gene_NNP expression_NN is_VBZ down_RB regulated_VBN by_IN promoter_NN
          hypermethylation_NN and_CC reactivated_VBN by_IN demethylation_NN
          To_TO examine_VB the_DT biological_JJ role_NN of_IN promoter_NN methylation_NN
          in_IN CC_NNP ,_, we_PRP assessed_VBD the_DT levels_NNS of_IN mRNA_NN by_IN
          semi-quantitative_JJ RT-PCR_NNP in_IN eight_CD cell_NN lines_NNS and_CC compared_VBN
          with_IN the_DT respective_JJ control_NN values_NNS obtained_VBN from_IN the_DT
          averages_NNS calculated_VBN from_IN 2_CD normal_JJ cervix_NN after_IN
          normalization_NN against_IN 
          ACTB_NNP ._. This_DT analysis_NN was_VBD performed_VBN
          on_IN 7_CD genes_NNS (_( 
          CDH_NNP 1_CD ,_, 
          DAPK_NNP ,_, 
          RARB_NNP ,_, 
          HIC_NNP 1_CD ,_, 
          MGMT_NNP ,_, 
          RASSF_NNP 1_CD A_DT ,_, 
          and_CC MLH_NNP 1_LS )_) that_WDT exhibited_VBN
          methylation_NN in_IN one_CD or_CC more_JJR cell_NN lines_NNS and_CC primary_JJ tumors_NNS
          (_( Fig_NNP ._. 3_LS )_) ._. 
          RARB_NNP gene_NN showed_VBD either_CC complete_JJ
          absence_NN of_IN or_CC down_RB regulated_VBN expression_NN in_IN all_DT cell_NN lines_NNS
          (_( 6_CD methylated_JJ and_CC 2_CD unmethylated_JJ )_) ._. Of_IN the_DT six_CD cell_NN lines_NNS
          with_IN 
          RARB_NNP gene_NN methylated_JJ ,_, three_CD (_( HT-_NNP 3_CD ,_,
          MS_NNP 751_CD ,_, and_CC ME-_NNP 180_CD )_) exhibited_VBN reactivation_NN upon_IN treatment_NN
          with_IN 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN or_CC n-butyrate_JJ alone_RB or_CC the_DT
          combination_NN of_IN the_DT two_CD ._. Three_CD cell_NN lines_NNS (_( C_NNP 4_CD -_: I_PRP ,_, CaSki_NNP ,_,
          and_CC SW_NNP 756_CD )_) that_WDT had_VBD promoter_NN methylation_NN of_IN 
          RARB_NNP did_VBD not_RB reactivate_NN expression_NN
          after_IN treatment_NN with_IN these_DT drugs_NNS (_( Fig_NNP ._. 4_LS )_) ._. One_CD of_IN the_DT two_CD
          unmethylated_JJ cell_NN lines_NNS also_RB reactivated_VBD the_DT expression_NN
          of_IN 
          RARB_NNP ._.
          The_DT 
          CDH_NNP gene_NN exhibited_VBN a_DT complete_JJ
          absence_NN of_IN expression_NN in_IN one_CD cell_NN line_NN (_( SW_NNP 756_CD )_) that_WDT
          showed_VBD promoter_NN hypermethylation_NN and_CC two_CD other_JJ cell_NN lines_NNS
          (_( C-_NNP 33_CD A_DT and_CC SiHa_NNP )_) without_IN evidence_NN of_IN methylation_NN (_( Fig_NNP ._.
          3_LS )_) ._. The_DT SW_NNP 756_CD cell_NN line_NN with_IN methylation_NN and_CC one_CD of_IN the_DT
          two_CD unmethylated_JJ cell_NN lines_NNS showed_VBD reactivated_VBN expression_NN
          upon_IN treatment_NN with_IN 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN or_CC in_IN
          combination_NN with_IN n-butyrate_JJ ,_, but_CC not_RB with_IN n-butyrate_JJ
          alone_RB ._. The_DT remaining_VBG five_CD cell_NN lines_NNS neither_DT showed_VBN
          evidence_NN of_IN decreased_VBD mRNA_NN nor_CC any_DT effect_NN of_IN
          demethylating_VBG or_CC HDAC-inhibiting_NNP agents_NNS on_IN expression_NN
          levels_NNS ._.
          The_DT 
          DAPK_NNP gene_NN showed_VBD a_DT complete_JJ absence_NN
          of_IN expression_NN in_IN five_CD and_CC down_RB regulated_VBN expression_NN in_IN
          one_CD of_IN the_DT 8_CD CC_NNP cell_NN lines_NNS studied_VBN (_( Fig_NNP ._. 3_LS )_) ._. Of_IN the_DT six_CD
          cell_NN lines_NNS with_IN down_RB regulated_VBN expression_NN ,_, 2_CD had_VBD promoter_NN
          methylation_NN and_CC 4_CD had_VBD unmethylated_JJ promoter_NN of_IN the_DT 
          DAPK_NNP gene_NN ._. Both_DT methylated_JJ cell_NN
          lines_NNS (_( HT-_NNP 3_CD and_CC SiHa_NNP )_) and_CC three_CD (_( C-_NNP 33_CD A_DT ,_, MS_NNP 751_CD ,_, and_CC
          ME-_NNP 180_CD )_) of_IN the_DT four_CD unmethylated_JJ cell_NN lines_NNS showed_VBD
          reactivation_NN upon_IN exposure_NN to_TO 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN or_CC
          in_IN combination_NN with_IN n-butyrate_JJ ._. One_CD of_IN the_DT unmethylated_JJ
          cell_NN lines_NNS (_( SW_NNP 756_CD )_) that_WDT showed_VBD a_DT complete_JJ absence_NN of_IN
          expression_NN did_VBD not_RB reactivate_NN after_IN treatment_NN ._.
          The_DT 
          HIC_NNP 1_CD gene_NN was_VBD methylated_JJ in_IN 5_CD of_IN 8_CD
          cell_NN lines_NNS ._. Three_CD of_IN the_DT methylated_JJ cell_NN lines_NNS (_( C-_NNP 4_CD I_PRP ,_,
          SiHa_NNP ,_, and_CC ME-_NNP 180_CD )_) and_CC one_CD of_IN the_DT three_CD unmethylated_JJ cell_NN
          lines_NNS (_( MS_NNP 751_CD )_) showed_VBD down_RB regulated_VBN expression_NN ._. Treatment_NNP
          of_IN 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN or_CC n-butyrate_JJ alone_RB or_CC the_DT
          combination_NN of_IN both_DT activated_VBN gene_NN expression_NN in_IN all_PDT the_DT
          cell_NN lines_NNS ,_, whether_IN or_CC not_RB promoter_NN had_VBD detectable_JJ
          methylation_NN (_( Fig_NNP ._. 4_LS )_) ._.
          The_DT 
          RASSF_NNP 1_CD A_DT gene_NN was_VBD methylated_JJ in_IN 3_CD
          cell_NN lines_NNS and_CC all_DT three_CD showed_VBD a_DT complete_JJ lack_NN of_IN
          expression_NN ._. None_NN of_IN the_DT unmethylated_JJ cell_NN lines_NNS showed_VBD
          evidence_NN of_IN down-regulated_JJ expression_NN of_IN 
          RASSF_NNP 1_CD A_DT mRNA_NN ._. Two_CD of_IN three_CD cell_NN
          lines_NNS with_IN 
          RASSF_NNP 1_CD A_DT methylation_NN and_CC complete_JJ
          lack_NN of_IN expression_NN reactivated_VBD upon_IN treatment_NN with_IN
          5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN alone_RB or_CC in_IN combination_NN with_IN
          n-butyrate_JJ ._. One_CD of_IN the_DT methylated_JJ cell_NN lines_NNS (_( HT-_NNP 3_LS )_) ,_,
          however_RB ,_, did_VBD not_RB reactivate_NN gene_NN expression_NN after_IN
          treatment_NN ._. The_DT unmethylated_JJ cell_NN lines_NNS showed_VBD normal_JJ
          expression_NN and_CC the_DT treatment_NN had_VBD no_DT effect_NN on_IN
          expression_NN ._.
          
          MGMT_NNP was_VBD methylated_JJ in_IN two_CD cell_NN
          lines_NNS ._. One_CD of_IN the_DT two_CD methylated_JJ cell_NN lines_NNS (_( CaSki_NNP )_)
          showed_VBD a_DT complete_JJ absence_NN of_IN expression_NN while_IN the_DT other_JJ
          methylated_JJ cell_NN line_NN (_( SW_NNP 756_CD )_) showed_VBD normal_JJ levels_NNS of_IN
          expression_NN ._. Treatment_NNP with_IN demethylating_VBG and_CC
          deacetylating_VBG inhibitor_NN did_VBD not_RB activate_VBP the_DT expression_NN
          in_IN any_DT cell_NN line_NN regardless_RB of_IN promoter_NN methylation_NN ._. 
          MLH_NNP 1_CD gene_NN was_VBD methylated_JJ in_IN one_CD
          cell_NN line_NN (_( SW_NNP 756_CD )_) but_CC we_PRP found_VBD no_DT evidence_NN of_IN
          down-regulated_JJ expression_NN in_IN this_DT cell_NN line_NN (_( data_NNS not_RB
          shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        Genetic_JJ alterations_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT
        development_NN of_IN CC_NNP [_NN 4_CD 7_CD 8_CD ]_NN ._. Our_PRP$ extensive_JJ molecular_JJ
        analyses_NNS identified_VBD a_DT number_NN of_IN specific_JJ genetic_JJ changes_NNS in_IN
        invasive_JJ CC_NNP and_CC its_PRP$ precursor_NN lesions_NNS [_NN 6_CD 14_CD 15_CD 16_CD 17_CD 18_CD 19_CD
        ]_NN ._. However_RB ,_, epigenetic_JJ alteration_NN in_IN cervical_JJ
        tumorigenesis_NNS is_VBZ not_RB well_RB characterized_VBN [_NN 12_CD 13_CD ]_NN ._. In_IN the_DT
        present_JJ study_NN ,_, we_PRP identified_VBD an_DT overall_JJ methylation_NN in_IN
        87_CD ._. 8_CD %_NN CC_NNP cases_NNS ._. Previous_JJ studies_NNS by_IN Dong_NNP et_CC al_NN (_( 79_CD %_NN )_) and_CC
        Virmani_NNP et_CC al_NN (_( 72_CD ._. 4_LS %_NN )_) have_VBP also_RB reported_VBN a_DT similar_JJ overall_JJ
        high_JJ frequency_NN of_IN promoter_NN methylation_NN [_NN 12_CD 13_CD ]_NN ._. We_PRP
        identified_VBD promoter_NN methylation_NN in_IN >_NN 25_CD %_NN cases_NNS in_IN 
        CDH_NNP 1_CD ,_, 
        DAPK_NNP ,_, and_CC 
        RARB_NNP genes_NNS ,_, while_IN it_PRP was_VBD less_RBR
        frequent_JJ (_( 10_CD -_: 25_CD %_NN cases_NNS )_) in_IN 
        HIC_NNP 1_CD ,_, 
        FHIT_NNP ,_, 
        RASSF_NNP 1_CD A_DT ,_, and_CC 
        APC_NNP genes_NNS in_IN CC_NNP patients_NNS ._. The_DT
        promoters_NNS of_IN 
        CDKN_NNP 2_CD A_DT ,_, 
        MGMT_NNP ,_, 
        BRCA_NNP 1_CD ,_, 
        TP_NNP 73_CD ,_, 
        TIMP_NNP 3_CD ,_, 
        GSTP_NNP 1_CD ,_, and_CC 
        MLH_NNP 1_CD genes_NNS were_VBD rarely_RB (_( <_NN 10_CD %_NN
        cases_NNS )_) methylated_JJ ._.
        
        CDH_NNP 1_CD is_VBZ the_DT most_RBS commonly_RB methylated_JJ
        gene_NN in_IN the_DT present_JJ study_NN showing_VBG promoter_NN methylation_NN in_IN
        51_CD ._. 1_LS %_NN of_IN CC_NNP cases_NNS ._. Dong_NNP and_CC co-workers_NNS have_VBP shown_VBN earlier_RBR
        that_IN the_DT 
        CDH_NNP 1_CD promoter_NN is_VBZ methylated_JJ in_IN 28_CD %_NN of_IN
        invasive_JJ CC_NNP [_NN 13_CD ]_NN ._. E-_NNP cadherin_NN ,_, 
        CDH_NNP 1_CD ,_, is_VBZ a_DT major_JJ adhesion_NN component_NN
        of_IN epithelial_NN cells_NNS ,_, which_WDT plays_VBZ an_DT important_JJ role_NN as_IN an_DT
        invasion_NN suppressor_NN gene_NN ._. Loss_NN of_IN function_NN of_IN 
        CDH_NNP 1_CD gene_NN has_VBZ been_VBN shown_VBN to_TO occur_VB in_IN
        widespread_JJ of_IN epithelial_NN tumor_NN types_NNS by_IN mutational_NN or_CC
        promoter_NN hypermethylation_NN mechanisms_NNS [_NN 11_CD 20_CD ]_NN ._. We_PRP have_VBP
        also_RB identified_VBN loss_NN of_IN expression_NN of_IN 
        CDH_NNP 1_CD gene_NN in_IN 37_CD ._. 5_LS %_NN of_IN CC_NNP cell_NN lines_NNS
        analyzed_VBD ._. Thus_RB ,_, these_DT data_NNS suggest_VBP that_DT inactivation_NN of_IN the_DT
        
        CDH_NNP 1_CD gene_NN by_IN promoter_NN methylation_NN
        plays_VBZ a_DT major_JJ role_NN in_IN CC_NNP tumorigenesis_NNS ._. However_RB ,_, our_PRP$
        immunohistochemical_JJ analysis_NN of_IN E-_NNP cadherin_NN protein_NN showed_VBD
        no_DT evidence_NN of_IN decreased_VBD expression_NN in_IN precursor_NN CIN_NNP
        lesions_NNS ._. Therefore_RB ,_, these_DT data_NNS indicate_VBP that_IN the_DT
        methylation_NN of_IN 
        CDH_NNP 1_CD gene_NN is_VBZ a_DT late_JJ event_NN in_IN the_DT
        development_NN of_IN CC_NNP ._.
        
        DAPK_NNP gene_NN is_VBZ methylated_JJ in_IN 43_CD ._. 3_LS %_NN
        cases_NNS in_IN the_DT present_JJ study_NN ._. Dong_NNP and_CC co-workers_NNS also_RB
        previously_RB showed_VBD promoter_NN methylation_NN in_IN 51_CD %_NN of_IN CC_NNP [_NN 13_CD ]_NN
        ._. 
        DAPK_NNP is_VBZ a_DT positive_JJ mediator_NN of_IN the_DT
        programmed_VBN cell_NN death_NN induced_VBN by_IN gamma-interferon_JJ [_NN 21_CD ]_NN ._.
        Loss_NN of_IN 
        DAPK_NNP expression_NN has_VBZ been_VBN shown_VBN to_TO
        occur_VB in_IN a_DT number_NN of_IN human_JJ malignancies_NNS ,_, primarily_RB by_IN
        promoter_NN hypermethylation_NN [_NN 11_CD ]_NN ._. It_PRP has_VBZ also_RB been_VBN shown_VBN
        that_DT loss_NN of_IN 
        DAPK_NNP gene_NN expression_NN was_VBD associated_VBN
        with_IN aggressive_JJ and_CC metastatic_JJ phenotype_NN in_IN many_JJ tumor_NN
        types_NNS [_NN 22_CD ]_NN ._. In_IN the_DT present_JJ study_NN ,_, in_IN addition_NN to_TO showing_VBG
        high_JJ frequency_NN of_IN promoter_NN methylation_NN of_IN 
        DAPK_NNP gene_NN ,_, we_PRP found_VBD a_DT complete_JJ lack_NN
        of_IN expression_NN in_IN two_CD of_IN the_DT methylated_JJ cell_NN lines_NNS and_CC four_CD
        of_IN 6_CD unmethylated_JJ cell_NN lines_NNS ._. Thus_RB ,_, our_PRP$ results_NNS suggest_VBP
        that_DT loss_NN of_IN expression_NN occurs_VBZ in_IN CC_NNP cell_NN lines_NNS by_IN
        mechanism_NN other_JJ than_IN complete_JJ promoter_NN methylation_NN ._.
        Therefore_RB ,_, our_PRP$ data_NNS further_JJ suggest_VBP a_DT role_NN for_IN 
        DAPK_NNP in_IN CC_NNP tumorigenesis_NNS ._.
        The_DT third_JJ most_RBS commonly_RB methylated_JJ gene_NN in_IN the_DT present_JJ
        study_NN is_VBZ 
        RARB_NNP ._. A_DT previous_JJ study_NN also_RB has_VBZ
        reported_VBN promoter_NN methylation_NN in_IN 33_CD ._. 3_LS %_NN of_IN invasive_JJ CC_NNP ,_, and_CC
        11_CD %_NN and_CC 29_CD %_NN of_IN low-_JJ and_CC high-grade_JJ CIN_NNP lesions_NNS ,_,
        respectively_RB [_NN 12_CD ]_NN ._. These_DT authors_NNS suggest_VBP that_IN 
        RARB_NNP methylation_NN is_VBZ an_DT early_JJ event_NN in_IN
        multistage_NN cervical_JJ carcinogenesis_NNS ._. Our_PRP$ semi-quantitative_JJ
        analysis_NN of_IN 
        RARB_NNP gene_NN expression_NN by_IN RT-PCR_NNP showed_VBD
        down-regulated_JJ expression_NN in_IN all_PDT the_DT eight_CD cell_NN lines_NNS
        analyzed_VBD whether_IN or_CC not_RB the_DT promoter_NN methylated_JJ (_( Fig_NNP ._. 3_LS )_) ._.
        In_IN addition_NN ,_, our_PRP$ immunohistochemical_JJ analysis_NN of_IN RARB_NNP
        showed_VBD lack_NN of_IN expression_NN in_IN 60_CD %_NN of_IN high-grade_JJ CINs_NNP ._. It_PRP has_VBZ
        been_VBN reported_VBN that_IN 
        RARB_NNP mRNA_NN is_VBZ down_RB regulated_VBN in_IN a_DT
        number_NN of_IN tumor_NN types_NNS [_NN 23_CD ]_NN ,_, including_VBG cervical_JJ cancer_NN [_NN
        24_CD ]_NN ._. Taken_VBN together_RB ,_, these_DT data_NNS support_VBP the_DT concept_NN that_IN 
        RARB_NNP play_VB an_DT important_JJ role_NN early_RB in_IN
        cervical_JJ cancer_NN progression_NN ._. The_DT direct_JJ role_NN of_IN 
        RARB_NNP in_IN regulating_VBG gene_NN expression_NN
        and_CC its_PRP$ retinoid-mediated_JJ antiproliferative_JJ ,_,
        differentiative_JJ ,_, immuno-modulatory_JJ ,_, and_CC apoptotic-inducing_JJ
        properties_NNS may_MD offer_VB a_DT therapeutic_JJ target_NN in_IN the_DT future_NN for_IN
        CC_NNP treatment_NN [_NN 25_CD ]_NN ._.
        As_IN reported_VBD in_IN a_DT previous_JJ study_NN ,_, we_PRP also_RB found_VBD promoter_NN
        methylation_NN of_IN 
        HIC_NNP 1_CD in_IN 22_CD ._. 2_LS %_NN of_IN CC_NNP [_NN 13_CD ]_NN ._. 
        HIC_NNP 1_CD is_VBZ a_DT zinc_NN finger_NN transcription_NN
        factor_NN that_WDT is_VBZ transcriptionally_RB silenced_VBN by_IN promoter_NN
        methylation_NN in_IN several_JJ types_NNS of_IN human_JJ cancer_NN [_NN 26_CD ]_NN ._.
        Heterozygous_NNP 
        Hic_NNP 1_CD mouse_NN with_IN promoter_NN methylation_NN
        of_IN wild_JJ type_NN allele_NN develop_VB carcinomas_NNS ,_, sarcomas_NNS and_CC
        lymphomas_NNS ,_, suggesting_VBG that_IN this_DT gene_NN acts_NNS as_IN a_DT tumor_NN
        suppressor_NN gene_NN [_NN 27_CD ]_NN ._. 
        HIC_NNP 1_CD gene_NN was_VBD down_RB regulated_VBN in_IN
        majority_NN of_IN the_DT CC_NNP cell_NN lines_NNS examined_VBN by_IN us_PRP and_CC this_DT
        down-regulated_JJ expression_NN was_VBD reactivated_VBN upon_IN treatment_NN
        with_IN demethylating_VBG and_CC HDAC-inhibiting_NNP agents_NNS ._. These_DT
        results_NNS support_VBP the_DT tumor_NN suppressor_NN role_NN of_IN 
        HIC_NNP 1_CD and_CC its_PRP$ inactivation_NN by_IN promoter_NN
        methylation_NN in_IN CC_NNP may_MD be_VB a_DT critical_JJ epigenetic_JJ change_NN in_IN
        tumor_NN development_NN ._.
        The_DT present_JJ methylation_NN profile_NN of_IN CC_NNP identified_VBD
        significant_JJ differences_NNS in_IN the_DT methylated_JJ genes_NNS between_IN SCC_NNP
        and_CC AC_NNP ._. We_PRP found_VBD that_DT methylation_NN of_IN 
        HIC_NNP 1_CD ,_, 
        APC_NNP ,_, and_CC 
        BRACA_NNP 1_CD genes_NNS was_VBD more_RBR common_JJ in_IN AC_NNP
        while_IN 
        CDH_NNP 1_CD promoter_NN methylation_NN was_VBD seen_VBN
        only_RB in_IN SCC_NNP ._. Such_JJ differences_NNS in_IN the_DT two_CD major_JJ histologies_NNS
        have_VBP also_RB been_VBN reported_VBN previously_RB for_IN 
        DAPK_NNP ,_, 
        HIC_NNP 1_CD ,_, and_CC 
        APC_NNP genes_NNS [_NN 13_CD ]_NN ._. However_RB ,_, we_PRP found_VBD 
        CDH_NNP 1_CD promoter_NN methylation_NN restricted_VBN
        to_TO SCC_NNP in_IN the_DT present_JJ study_NN ,_, while_IN Dong_NNP et_CC al_NN found_VBD
        methylation_NN in_IN both_DT histological_JJ types_NNS [_NN 13_CD ]_NN ._. This_DT
        difference_NN may_MD be_VB due_JJ to_TO small_JJ number_NN of_IN AC_NNP patients_NNS we_PRP
        studied_VBD ._. Distinct_NNP patterns_NNS of_IN promoter_NN methylation_NN between_IN
        SCC_NNP and_CC AC_NNP ,_, however_RB ,_, suggest_VBP that_IN epigenetic_JJ pathways_NNS of_IN
        tumor_NN suppression_NN may_MD be_VB different_JJ in_IN these_DT histologic_JJ
        subtypes_NNS ._. Contrary_JJ to_TO the_DT previous_JJ reports_NNS ,_, we_PRP found_VBD a_DT low_JJ
        frequency_NN of_IN 
        p_NN 16_CD /_NN CDKN_NNP 2_CD A_DT gene_NN promoter_NN methylation_NN
        [_NN 12_CD 13_CD 28_CD 29_CD ]_NN ._. The_DT reason_NN for_IN these_DT differences_NNS is_VBZ
        currently_RB unclear_JJ ._.
        Our_PRP$ statistical_JJ correlative_JJ analysis_NN of_IN promoter_NN
        methylation_NN with_IN clinicopathologic_JJ parameters_NNS ,_, HPV_NNP type_NN ,_,
        and_CC microsatellite_NN instability_NN identified_VBD significant_JJ
        associations_NNS ._. A_DT most_RBS significant_JJ finding_NN was_VBD that_IN overall_JJ
        promoter_NN hypermethylation_NN is_VBZ associated_VBN with_IN the_DT
        progression_NN and_CC predicts_VBZ significantly_RB poor_JJ disease-free_JJ
        survival_NN ._. This_DT was_VBD most_RBS evident_JJ in_IN 
        BRCA_NNP 1_CD and_CC 
        MGMT_NNP genes_NNS ,_, where_WRB all_PDT the_DT patients_NNS
        with_IN promoter_NN methylation_NN were_VBD dead_JJ (_( Table_NNP 2_LS )_) ._. The_DT
        multivariate_NN Cox_NNP regression_NN analysis_NN showed_VBD that_DT promoter_NN
        methylation_NN is_VBZ an_DT independent_JJ predictor_NN of_IN outcome_NN for_IN 
        BRCA_NNP 1_CD (_( 3_CD -_: fold_VB risk_NN )_) and_CC 
        MGMT_NNP (_( 2_CD ._. 3_LS fold_VB risk_NN )_) genes_NNS ._. Promoter_NNP
        methylation_NN of_IN cancer-related_JJ genes_NNS has_VBZ been_VBN reported_VBN to_TO
        predict_VB patient_NN prognosis_NN for_IN a_DT number_NN of_IN genes_NNS [_NN 30_CD 31_CD ]_NN ._.
        
        BRCA_NNP 1_CD plays_VBZ a_DT critical_JJ role_NN in_IN DNA_NNP
        repair_NN and_CC recombination_NN ,_, cell_NN cycle_NN checkpoint_NN control_NN ,_,
        and_CC transcription_NN ._. This_DT gene_NN has_VBZ been_VBN shown_VBN to_TO be_VB
        hypermethylated_JJ in_IN tumors_NNS arising_VBG from_IN breast-ovarian_JJ
        cancer_NN syndrome_NN [_NN 32_CD ]_NN ._. Although_IN we_PRP detected_VBD complete_JJ
        promoter_NN methylation_NN of_IN 
        BRCA_NNP 1_CD gene_NN in_IN only_RB 6_CD %_NN of_IN primary_JJ
        tumors_NNS ,_, other_JJ mechanisms_NNS that_WDT inactivate_NN this_DT gene_NN might_MD
        exist_VB ._. The_DT present_JJ MSP_NNP data_NNS and_CC its_PRP$ relation_NN to_TO poor_JJ
        clinical_JJ outcome_NN warrants_VBZ a_DT further_JJ study_NN of_IN 
        BRCA_NNP 1_CD role_NN in_IN CC_NNP ._. 
        MGMT_NNP gene_NN encodes_NNS
        O_NNP (_( 6_CD )_) -_: methylguanine-_NN DNA_NNP methyltransferase_NN and_CC this_DT enzyme_NN
        effectively_RB removes_VBZ DNA_NNP adducts_NNS formed_VBN by_IN alkylating_VBG agents_NNS
        [_NN 33_CD ]_NN ._. Epigenetic_NNP gene_NN silencing_VBG of_IN 
        MGMT_NNP confers_VBZ enhanced_JJ sensitivity_NN to_TO
        alkylating-based_JJ chemotherapy_NN ,_, and_CC lack_NN of_IN methylation_NN
        associates_NNS with_IN failure_NN to_TO respond_VB to_TO chemotherapy_NN [_NN 34_CD 35_CD
        ]_NN ._. On_IN the_DT contrary_NN ,_, all_DT patients_NNS that_WDT had_VBD 
        MGMT_NNP promoter_NN methylation_NN were_VBD dead_JJ
        within_IN 21_CD months_NNS of_IN initial_JJ diagnosis_NN ,_, which_WDT predicts_VBZ a_DT
        poor_JJ prognosis_NN ._. A_DT possible_JJ explanation_NN for_IN this_DT failure_NN to_TO
        respond_VB may_MD be_VB that_IN all_PDT the_DT four_CD patients_NNS in_IN the_DT present_JJ
        study_NN were_VBD treated_VBN only_RB with_IN radiotherapy_NN with_IN or_CC without_IN
        combination_NN of_IN surgery_NN ._. The_DT standard_JJ treatment_NN for_IN
        advanced-stage_JJ cervix_NN cancer_NN has_VBZ been_VBN the_DT combination_NN of_IN
        radical_JJ surgery_NN and_CC radiotherapy_NN [_NN 36_CD ]_NN ._. The_DT utility_NN of_IN
        cytotoxic_JJ chemotherapy_NN in_IN patients_NNS with_IN advanced_VBD CC_NNP has_VBZ
        been_VBN recognized_VBN recently_RB [_NN 37_CD ]_NN ._. Thus_RB ,_, the_DT epigenetic_JJ gene_NN
        silencing_VBG of_IN 
        MGMT_NNP ,_, although_IN in_IN a_DT small_JJ
        proportion_NN ,_, may_MD serve_VB as_IN indicator_NN of_IN responsiveness_NNS to_TO
        treatment_NN with_IN chemotherapeutic_JJ drugs_NNS that_WDT cause_VBP DNA_NNP
        adducts_NNS in_IN CC_NNP ._.
        Most_JJS patients_NNS in_IN the_DT present_JJ study_NN population_NN were_VBD
        treated_VBN with_IN traditional_JJ radiation_NN and_CC surgery_NN treatment_NN
        protocols_NNS ._. To_TO assess_VB the_DT impact_NN of_IN promoter_NN methylation_NN on_IN
        treatment_NN ,_, we_PRP compared_VBD the_DT patients_NNS followed_VBN for_IN more_JJR than_IN
        5_CD months_NNS after_IN treatment_NN ._. This_DT analysis_NN suggests_VBZ that_IN 
        RARB_NNP methylation_NN predict_VBP a_DT worse_JJR
        prognosis_NN (_( P_NN =_SYM 0_CD ._. 02_CD )_) ._. Twelve_CD of_IN the_DT 15_CD (_( 80_CD %_NN )_) patients_NNS with_IN 
        RARB_NNP methylation_NN were_VBD DOC_NNP or_CC did_VBD not_RB
        respond_VB to_TO the_DT current_JJ treatment_NN ,_, while_IN only_RB 3_CD of_IN the_DT 15_CD
        (_( 20_CD %_NN )_) patients_NNS with_IN 
        RARB_NNP methylation_NN exhibited_VBN complete_JJ
        response_NN ._. Since_IN 
        RARB_NNP functions_NNS as_IN a_DT tumor_NN suppressor_NN
        gene_NN and_CC its_PRP$ chemopreventive_JJ effects_NNS are_VBP purely_RB based_VBN on_IN
        retinoid_NN induced_VBD reactivation_NN ,_, the_DT patients_NNS that_WDT received_JJ
        radiation_NN therapy_NN will_MD have_VB no_DT effect_NN on_IN these_DT tumors_NNS ._. Our_PRP$
        data_NNS ,_, therefore_RB ,_, suggest_VBP that_IN the_DT CC_NNP patients_NNS showing_VBG 
        RARB_NNP promoter_NN methylation_NN may_MD benefit_VB
        from_IN targeted_VBN chemopreventive_JJ treatment_NN of_IN combination_NN of_IN
        retinoic_JJ acid_NN ,_, demethylating_VBG ,_, and_CC chromatin_NN modifying_VBG
        agents_NNS that_WDT reactivate_NN the_DT gene_NN expression_NN ._. An_DT
        understanding_NN of_IN the_DT exact_JJ mechanisms_NNS of_IN 
        RARB_NNP loss_NN of_IN function_NN in_IN CC_NNP is_VBZ
        essential_JJ for_IN such_JJ a_DT strategy_NN ._.
        Microsatellite_NNP instability_NN (_( MSI_NNP )_) is_VBZ hallmark_NN of_IN mismatch_NN
        repair-deficient_JJ cancers_NNS ,_, which_WDT has_VBZ been_VBN observed_VBN in_IN all_DT
        cancers_NNS arising_VBG from_IN Hereditary_NNP Non-polyposis_NNP Colorectal_NNP
        Cancer_NNP (_( HNPCC_NNP )_) syndrome_NN ,_, some_DT sporadic_JJ colorectal_NN and_CC other_JJ
        cancers_NNS [_NN 38_CD ]_NN ._. MSI_NNP is_VBZ generally_RB associated_VBN with_IN germ-line_JJ
        mutations_NNS in_IN one_CD of_IN two_CD MMR_NNP genes_NNS ,_, 
        hMLH_NN 1_CD and_CC 
        hMSH_NN 2_CD ._. Epigenetic_NNP inactivation_NN of_IN
        promoter_NN hypermethylation_NN of_IN 
        APC_NNP and_CC 
        HIC_NNP 1_CD also_RB results_VBZ in_IN MSI_NNP phenotype_NN in_IN
        sporadic_JJ colorectal_NN cancers_NNS [_NN 39_CD 40_CD ]_NN ._. Accumulating_NNP
        evidence_NN supports_VBZ the_DT view_NN that_DT promoter_NN methylation_NN of_IN
        mismatch_NN repair_NN genes_NNS may_MD be_VB related_VBN to_TO MSI_NNP phenotype_NN [_NN 41_CD
        42_CD ]_NN ._. A_DT number_NN of_IN previous_JJ studies_NNS have_VBP shown_VBN the_DT
        existence_NN of_IN MSI_NNP phenotype_NN in_IN CC_NNP [_NN 43_CD 44_CD ]_NN ._. In_IN the_DT present_JJ
        study_NN ,_, we_PRP found_VBD that_IN MSI-H_NNP occurs_VBZ at_IN an_DT increased_VBN frequency_NN
        in_IN tumors_NNS with_IN 
        HIC_NNP 1_CD and_CC 
        APC_NNP promoter_NN hypermethylation_NN ._.
        Association_NNP of_IN 
        APC_NNP promoter_NN methylation_NN with_IN MSI_NNP
        phonotype_NN has_VBZ been_VBN previously_RB reported_VBN in_IN endometrial_NN
        cancer_NN [_NN 45_CD ]_NN ._. Although_IN the_DT significance_NN of_IN these_DT results_NNS
        is_VBZ currently_RB unclear_JJ ,_, we_PRP believe_VBP that_DT inactivation_NN of_IN these_DT
        genes_NNS by_IN promoter_NN methylation_NN causes_NNS microsatellite_NN
        instability_NN and_CC may_MD contribute_VB to_TO the_DT development_NN of_IN
        CC_NNP ._.
        Aberrant_NNP promoter_NN methylation_NN changes_NNS that_WDT occur_VBP in_IN
        cancer_NN are_VBP associated_VBN with_IN transcriptional_NN repression_NN and_CC
        loss_NN of_IN function_NN of_IN the_DT methylated_JJ gene_NN [_NN 9_CD ]_NN ._. Since_IN we_PRP
        found_VBD evidence_NN of_IN down-regulated_JJ expression_NN of_IN several_JJ
        methylated_JJ genes_NNS in_IN CC_NNP cell_NN lines_NNS ,_, we_PRP tested_VBD to_TO see_VB if_IN this_DT
        down-regulation_JJ could_MD be_VB reactivated_VBN by_IN methylation_NN and_CC
        HDAC-inhibiting_NNP agents_NNS ._. Transcriptional_NNP silencing_VBG of_IN genes_NNS
        resulting_VBG from_IN DNA_NNP hypermethylation_NN of_IN CpG_NNP islands_NNS is_VBZ
        reversed_VBN by_IN treatment_NN with_IN the_DT hypo-methylating_JJ agent_NN
        5_CD -_: aza-_NN 2_CD '_POS -_: deoxycytidine_NN and_CC HDAC-inhibiting_NNP agent_NN n-butyrate_JJ
        in_IN a_DT dose_NN and_CC duration-dependent_JJ manner_NN ._. We_PRP found_VBD that_IN
        5_CD -_: Aza-_NNP 2_CD '_POS -_: deoxycytidine_NN treatment_NN alone_RB or_CC in_IN combination_NN
        with_IN n-butyrate_JJ resulted_VBD in_IN reactivation_NN of_IN gene_NN expression_NN
        in_IN most_JJS cell_NN lines_NNS that_WDT showed_VBD promoter_NN methylation_NN ._. In_IN
        some_DT cell_NN lines_NNS ,_, exposure_NN to_TO n-butyrate_JJ alone_RB has_VBZ resulted_VBN
        in_IN reactivation_NN of_IN the_DT gene_NN expression_NN ,_, for_IN example_NN in_IN 
        HIC_NNP 1_CD gene_NN (_( Fig_NNP ._. 4_LS )_) ._. These_DT data_NNS ,_,
        therefore_RB ,_, suggest_VBP that_IN other_JJ epigenetic_JJ mechanisms_NNS
        involving_VBG defects_NNS in_IN chromatin_NN modification_NN factors_NNS such_JJ as_IN
        acetylation_NN and_CC methylation_NN of_IN histone_NN proteins_NNS may_MD also_RB
        play_VB role_NN in_IN gene_NN silencing_VBG ._. Thus_RB ,_, our_PRP$ data_NNS also_RB suggest_VBP
        that_IN epigenetic_JJ changes_NNS that_WDT accompany_VB methylation_NN are_VBP
        common_JJ in_IN CC_NNP and_CC play_VB critical_JJ role_NN in_IN CC_NNP development_NN ._.
      
      
        Conclusions_NNP
        The_DT present_JJ study_NN identified_VBD promoter_NN methylation_NN in_IN a_DT
        number_NN of_IN genes_NNS in_IN CC_NNP ._. The_DT most_RBS frequently_RB methylated_JJ genes_NNS
        were_VBD 
        CDH_NNP 1_CD ,_, 
        DAPK_NNP ,_, 
        RARB_NNP ,_, and_CC 
        HIC_NNP 1_CD ._. We_PRP have_VBP also_RB shown_VBN that_DT
        promoter_NN methylation_NN of_IN these_DT genes_NNS result_VBP in_IN
        transcriptional_NN repression_NN ._. Furthermore_RB ,_, 
        RARB_NNP gene_NN expression_NN is_VBZ down_RB
        regulated_VBN in_IN high-grade_JJ CINs_NNP ._. These_DT data_NNS suggest_VBP that_IN some_DT
        of_IN the_DT methylated_JJ genes_NNS may_MD play_VB a_DT role_NN early_RB in_IN the_DT
        progression_NN of_IN cancer_NN ._. Here_RB we_PRP showed_VBD that_DT promoter_NN
        methylation_NN is_VBZ associated_VBN with_IN advanced_JJ stage_NN of_IN the_DT
        disease_NN ,_, 
        RARB_NNP and_CC 
        BRCA_NNP 1_CD promoter_NN methylation_NN predict_VBP a_DT
        worse_JJR prognosis_NN ,_, and_CC the_DT 
        HIC_NNP 1_CD and_CC 
        APC_NNP promoter_NN methylation_NN is_VBZ
        frequently_RB associated_VBN with_IN MSI_NNP ._. This_DT knowledge_NN of_IN
        epigenetic_JJ changes_NNS in_IN CC_NNP may_MD have_VB implications_NNS in_IN our_PRP$
        understanding_NN of_IN the_DT role_NN they_PRP play_VBP in_IN CC_NNP development_NN ._.
        Particularly_RB ,_, if_IN the_DT present_JJ results_NNS are_VBP replicated_VBN and_CC
        identified_VBN in_IN precancerous_JJ lesions_NNS ,_, this_DT may_MD be_VB useful_JJ in_IN
        predicting_VBG the_DT high-risk_JJ lesions_NNS to_TO progression_NN and_CC serve_VB
        as_IN targets_NNS of_IN treatment_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS ,_, Tumor_NNP tissues_NNS ,_, and_CC cell_NN lines_NNS
          A_DT total_NN of_IN 82_CD tumor_NN biopsies_NNS derived_VBN from_IN previously_RB
          untreated_JJ primary_JJ invasive_JJ CCs_NNP and_CC eight_CD cell_NN lines_NNS were_VBD
          used_VBN ._. The_DT tumor_NN biopsies_NNS were_VBD ascertained_JJ from_IN patients_NNS
          evaluated_VBN at_IN the_DT Instituto_NNP Nacional_NNP de_IN Cancerologia_NNP
          (_( Santa_NNP Fe_NNP de_IN Bogota_NNP ,_, Colombia_NNP )_) and_CC from_IN the_DT Department_NNP of_IN
          the_DT Obstetrics_NNP and_CC Gynecology_NNP of_IN Friedrich_NNP Schiller_NNP
          University_NNP ,_, Jena_NNP ,_, Germany_NNP after_IN appropriate_JJ informed_VBN
          consent_NN and_CC approval_NN of_IN protocols_NNS by_IN institutional_JJ review_NN
          boards_NNS ._. The_DT primary_JJ tumors_NNS were_VBD clinically_RB classified_VBN as_IN
          FIGO_NNP stage_NN IB_NNP (_( 17_CD tumors_NNS )_) ,_, IIB_NNP (_( 19_CD tumors_NNS )_) ,_, IIIB_NNP (_( 43_CD
          tumors_NNS )_) ,_, and_CC IV_NNP (_( 3_CD tumors_NNS )_) ._. Histologically_NNP ,_, 77_CD tumors_NNS
          were_VBD classified_VBN as_IN squamous_JJ cell_NN carcinoma_NN (_( SCC_NNP )_) and_CC five_CD
          as_IN adenocarcinoma_NN (_( AC_NNP )_) ._. Clinical_NNP information_NN such_JJ as_IN age_NN ,_,
          stage_NN and_CC size_NN of_IN the_DT tumor_NN ,_, follow-up_JJ after_IN treatment_NN
          was_VBD collected_VBN for_IN all_DT patients_NNS ._. Patient_NNP follow-up_JJ data_NNS
          was_VBD collected_VBN from_IN the_DT review_NN of_IN institutional_JJ medical_JJ
          records_NNS ,_, and_CC by_IN contacting_VBG outside_JJ physicians_NNS and_CC
          institutions_NNS ._. The_DT follow_VB up_RB ranged_VBD from_IN 1_CD -_: 72_CD months_NNS ._.
          Thirty-nine_NNP cervical_JJ intraepithelial_NN neoplastic_JJ lesions_NNS
          derived_VBN from_IN 37_CD patients_NNS were_VBD also_RB obtained_VBN as_IN
          formalin-fixed_JJ and_CC paraffin-embedded_JJ archival_JJ tissues_NNS
          from_IN Columbia_NNP University_NNP and_CC Instituto_NNP Nacional_NNP de_IN
          Cancerologia_NNP (_( Santa_NNP Fe_NNP de_IN Bogota_NNP ,_, Colombia_NNP )_) ._. Eight_CD normal_JJ
          cervical_JJ swabs_NNS ,_, diagnosed_VBN on_IN Pap_NNP smear_NN as_IN normal_JJ squamous_JJ
          epithelium_NN ,_, were_VBD collected_VBN in_IN phosphate_NN buffer_NN saline_NN
          from_IN the_DT patients_NNS attending_VBG Gynecology_NNP Clinic_NNP at_IN the_DT
          Columbia_NNP Presbyterian_NNP Medical_NNP Center_NNP ,_, New_NNP York_NNP after_IN
          appropriate_JJ informed_VBN consent_NN ._. Cell_NNP pellets_NNS obtained_VBN from_IN
          the_DT swabs_NNS were_VBD used_VBN to_TO isolate_VB DNA_NNP ._. CC_NNP cell_NN lines_NNS SiHa_NNP ,_,
          SW_NNP 756_CD ,_, C-_NNP 4_CD I_PRP ,_, Ca_NNP Ski_NN ,_, C-_NNP 33_CD A_DT ,_, HT-_NNP 3_CD ,_, MS_NNP 751_CD and_CC ME-_NNP 180_CD were_VBD
          obtained_VBN from_IN the_DT American_NNP Type_NNP Culture_NNP Collection_NNP
          (_( Manassas_NNP ,_, VA_NNP )_) ,_, and_CC grown_VBN in_IN tissue_NN culture_NN according_VBG to_TO
          the_DT supplier_NN 's_POS recommendations_NNS ._. Frozen_NNP tumor_NN tissues_NNS or_CC
          cell_NN pellets_NNS were_VBD utilized_JJ for_IN isolating_VBG DNA_NNP and_CC /_NN or_CC RNA_NNP
          by_IN standard_JJ methods_NNS ._.
        
        
          Methylation_NNP Specific_JJ PCR_NNP (_( MSP_NNP )_)
          Genomic_NNP DNA_NNP was_VBD treated_VBN with_IN sodium_NN bisulphite_NN as_RB
          previously_RB described_VBD [_NN 46_CD ]_NN ._. Placental_NNP DNA_NNP treated_VBD in_IN
          vitro_NN with_IN 
          Sss_NNP I_PRP methyltransferase_NN (_( New_NNP
          England_NNP Biolabs_NNP ,_, Beverly_NNP ,_, MA_NNP )_) and_CC similarly_RB treated_VBN
          normal_JJ lymphocyte_NN DNA_NNP were_VBD used_VBN as_IN controls_NNS for_IN
          methylated_JJ and_CC unmethylated_JJ templates_NNS ,_, respectively_RB ._. The_DT
          primers_NNS used_VBN for_IN amplification_NN of_IN methylated_JJ and_CC
          unmethylated_JJ promoters_NNS of_IN genes_NNS 
          RARB_NNP ,_, 
          TIMP_NNP 3_CD ,_, 
          CDKN_NNP 2_CD A_DT ,_, 
          p_NN 14_CD 
          ARF_NNP ,_, 
          MGMT_NNP ,_, 
          DAPK_NNP ,_, 
          CDH_NNP 1_CD ,_, 
          GSTP_NNP 1_CD ,_, 
          APC_NNP promoter_NN 1_CD A_DT ,_, 
          RB_NNP 1_CD ,_, 
          MLH_NNP 1_CD ,_, 
          TP_NNP 73_CD ,_, 
          BRCA_NNP 1_CD ,_, 
          FHIT_NNP ,_, and_CC 
          HIC_NNP 1_CD have_VBP been_VBN described_VBN previously_RB
          http_NN :_: /_NN /_NN pathology_NN 2_CD ._. jhu_NN ._. edu_NN /_NN pancreas_NN /_NN prim_JJ 0425_CD ._. htm_NN #_# MSP_NNP ;_: [_NN 32_CD
          47_CD 48_CD 49_CD ]_NN ._. Methylated_NNP (_( MF_NNP and_CC MR_NNP )_) and_CC unmethylated_JJ (_( UF_NNP
          and_CC UR_NNP )_) primers_NNS for_IN 
          RASSF_NNP 1_CD A_DT promoter_NN were_VBD designed_VBN
          according_VBG to_TO Herman_NNP et_CC al_NN [_NN 46_CD ]_NN and_CC as_IN described_VBN earlier_JJR
          [_NN 50_CD ]_NN ._. PCR_NNP products_NNS were_VBD run_VBN on_IN 2_CD %_NN agarose_NN gels_NNS and_CC
          visualized_JJ after_IN ethidium_NN bromide_NN staining_VBG ._. Purified_NNP MSP_NNP
          products_NNS were_VBD sequenced_JJ in_IN representative_NN specimens_NNS by_IN
          direct_JJ sequencing_VBG to_TO confirm_VB the_DT methylation_NN identified_VBN
          on_IN agarose_NN gels_NNS ._.
        
        
          5_LS -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN and_CC n-butyrate_JJ treatment_NN ,_,
          and_CC analysis_NN of_IN gene_NN expression_NN
          Cell_NNP lines_NNS were_VBD treated_VBN with_IN demethylating_VBG agent_NN
          5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN (_( Sigma_NNP )_) for_IN five_CD days_NNS at_IN a_DT
          concentration_NN of_IN 2_CD to_TO 5_CD μM_NN ,_, HDAC-inhibiting_NNP agent_NN
          n-butyrate_JJ at_IN a_DT final_JJ concentration_NN of_IN 5_CD μM_NN for_IN the_DT last_JJ
          24_CD hours_NNS or_CC a_DT combination_NN of_IN both_DT ._. Total_NNP RNA_NNP isolated_VBD
          from_IN treated_VBN and_CC untreated_JJ cell_NN lines_NNS ,_, and_CC the_DT total_JJ RNA_NNP
          and_CC poly_RB A_DT +_NN RNA_NNP from_IN normal_JJ cervix_NN obtained_VBN from_IN Ambion_NNP
          (_( Austin_NNP ,_, TX_NNP )_) was_VBD reverse_VB transcribed_JJ using_VBG random_JJ primers_NNS
          and_CC the_DT Pro-_NNP STAR_NNP first_JJ strand_NN RT-PCR_NNP kit_NN (_( Stratagene_NNP ,_, La_NNP
          Jolla_NNP ,_, CA_NNP )_) ._. A_DT semi-quantitative_JJ analysis_NN of_IN gene_NN
          expression_NN was_VBD performed_VBN in_IN replicate_VB experiments_NNS using_VBG
          26_CD -_: 28_CD cycles_NNS of_IN multiplex_NN RT-PCR_NNP with_IN β-actin_JJ (_( 
          ACTB_NNP )_) as_IN control_NN and_CC gene_NN specific_JJ
          primers_NNS spanning_VBG at_IN least_JJS 2_CD exons_NNS ._. The_DT primers_NNS used_VBN for_IN 
          CDH_NNP 1_CD ,_, 
          MGMT_NNP ,_, 
          MLH_NNP 1_CD ,_, and_CC 
          RARB_NNP have_VBP been_VBN described_VBN earlier_JJR [_NN
          50_CD ]_NN ._. The_DT gene_NN primers_NNS used_VBN for_IN 
          DAPK_NNP and_CC 
          RASSF_NNP 1_CD A_DT and_CC their_PRP$ positions_NNS in_IN
          respective_JJ cDNAs_NNS were_VBD :_:
          
          DAPK-F_NNP 5_CD '_POS -_: CAGTTTGCGGTTGTGAAGAA-_NNP 3_CD '_POS
          (_( 403_CD -_: 422_CD bp_NN )_)
          
          DAPK-R_NNP 5_CD '_POS -_: CCTGCAACGAGTTCCAAGAT-_NNP 3_CD '_POS
          (_( 610_CD -_: 629_CD bp_NN )_)
          
          RASSF_NNP 1_CD A-F_NNP
          5_CD '_POS -_: GACCTCTGTGGCGACTTCAT-_NNP 3_CD '_POS (_( 232_CD -_: 251_CD bp_NN ,_, exon_NN 1_CD A_DT )_)
          
          
          RASSF_NNP 1_CD A-R_NNP 5_CD '_POS -_: GCTGTTGATCTGGGCATTGT-_NNP 3_CD '_POS (_( 461_CD -_: 480_CD bp_NN )_)
          The_DT PCR_NNP products_NNS were_VBD run_VBN on_IN 1_CD ._. 5_CD %_NN agarose_NN gels_NNS ,_,
          visualized_JJ by_IN ethidium_NN bromide_NN staining_VBG and_CC quantitated_JJ
          using_VBG the_DT Kodak_NNP Digital_NNP Image_NN Analysis_NNP System_NNP (_( Kodak_NNP ,_, New_NNP
          Haven_NNP ,_, CT_NNP )_) ._.
        
        
          Microsatellite_NNP analysis_NN
          High-molecular_NNP weight_NN DNA_NNP from_IN frozen_VBN tumor_NN and_CC the_DT
          corresponding_JJ peripheral_JJ blood_NN specimens_NNS was_VBD isolated_VBN as_RB
          previously_RB described_VBD [_NN 14_CD ]_NN ._. A_DT panel_NN of_IN 49_CD sequence_NN
          tagged_VBN repeat_NN polymorphic_JJ (_( STRP_NNP )_) (_( 24_CD markers_NNS mapped_VBN to_TO
          chromosome_NN 2_CD q_NN ,_, nine_CD on_IN 5_CD p_NN ,_, 11_CD on_IN 6_CD p_NN ,_, and_CC five_CD on_IN 11_CD q_NN )_)
          markers_NNS ,_, previously_RB analyzed_VBD for_IN LOH_NNP ,_, was_VBD chosen_VBN for_IN
          scoring_VBG MSI_NNP [_NN 14_CD 15_CD 16_CD 17_CD ]_NN ._. The_DT criterion_NN for_IN analysis_NN
          and_CC classification_NN of_IN MSI_NNP has_VBZ been_VBN described_VBN earlier_JJR [_NN 51_CD
          52_CD ]_NN ._.
        
        
          Detection_NNP of_IN HPV_NNP
          PCR_NNP amplification_NN with_IN PGMY_NNP 09_CD /_NN 11_CD L_NNP 1_CD consensus_NN HPV_NNP L_NNP 1_CD
          primers_NNS followed_VBN by_IN reverse_NN line_NN blot_NN hybridization_NN was_VBD
          used_VBN to_TO detect_VB 38_CD genital_JJ HPV_NNP types_NNS as_IN described_VBN earlier_JJR
          [_NN 53_CD 54_CD ]_NN ._. Appropriate_NNP control_NN experiments_NNS were_VBD set_VBN up_RP
          using_VBG bulk_NN master_NN mix_NN components_NNS to_TO eliminate_VB potential_JJ
          contamination_NN ._. Individual_JJ assay_NN sensitivity_NN was_VBD analyzed_VBN
          by_IN the_DT use_NN of_IN serial_NN dilutions_NNS of_IN SiHa_NNP cell_NN line_NN crude_NN
          cell_NN digest_VB ,_, targeting_VBG 10_CD 4_CD ,_, 10_CD 3_CD ,_, 10_CD 2_CD ,_, 10_CD 1_CD ,_, and_CC 10_CD
          0_CD input_NN copies_NNS of_IN HPV-_NNP 16_CD ._. A_DT no_DT template_NN negative_JJ control_NN
          was_VBD set_VBN up_RP in_IN all_DT experiments_NNS ._.
        
        
          Immunohistochemistry_NNP
          Four_CD μ-thick_JJ sections_NNS were_VBD cut_VBN from_IN paraffin-embedded_JJ
          blocks_NNS and_CC immuno-stained_JJ following_NN deparaffinization_NN and_CC
          antigen_NN retrieval_NN using_VBG citrate_NN buffer_NN at_IN pH_NN 6_CD ._. 0_CD ._.
          Following_VBG incubation_NN with_IN antibodies_NNS against_IN E-_NNP cadherin_NN
          (_( Dako_NNP ,_, Carpinteria_NNP ,_, CA_NNP )_) and_CC RARB_NNP (_( NeoMarkers_NNP ,_, Fremont_NNP ,_,
          CA_NNP )_) ,_, signal_NN was_VBD detected_VBN with_IN the_DT Envision_NNP plus_CC (_( DAKO_NNP ,_,
          Carpenteria_NNP ,_, CA_NNP )_) system_NN ,_, using_VBG diaminobenzidine_NN as_IN a_DT
          chromogen_NN ._. Tumors_NNP were_VBD considered_VBN positive_JJ for_IN E-_NNP cadherin_NN
          when_WRB cells_NNS showed_VBD membrane_NN staining_VBG ._. For_IN RARB_NNP ,_, staining_VBG
          in_IN normal_JJ epithelium_NN either_CC nuclear_JJ or_CC cytoplasmic_JJ or_CC
          both_DT were_VBD considered_VBN positive_JJ ._. Normal_NNP epithelium_NN and_CC
          mesenchymal_NN cell_NN expression_NN were_VBD used_VBN as_IN internal_JJ
          controls_NNS ._.
        
        
          Statistical_NNP Analysis_NNP
          We_PRP first_RB assessed_VBN associations_NNS between_IN presence_NN of_IN
          promoter_NN methylation_NN for_IN each_DT gene_NN and_CC various_JJ clinical_JJ ,_,
          demographic_JJ ,_, and_CC genetic_JJ characteristics_NNS using_VBG Chi-_NNP Square_NNP
          test_NN [_NN 55_CD ]_NN and_CC Fisher_NNP 's_POS Exact_JJ test_NN (_( for_IN small_JJ cell_NN
          counts_VBZ )_) [_NN 56_CD ]_NN ._. Characteristics_NNP that_IN we_PRP examined_VBD
          included_VBN :_: histology_NN ,_, stage_NN ,_, tumor_NN size_NN ,_, patient_NN 's_POS age_NN ,_,
          clinical_JJ outcome_NN ,_, treatment_NN response_NN ,_, HPV_NNP type_NN ,_, and_CC
          microsatellite_NN instability_NN ._. Cox_NNP Proportional_NNP Hazard_NNP
          Models_NNP [_NN 57_CD ]_NN were_VBD further_RBR applied_VBN to_TO assess_VB the_DT relative_JJ
          hazard_NN (_( risk_NN )_) of_IN dying_VBG associated_VBN with_IN each_DT methylated_JJ
          gene_NN after_IN adjusting_VBG for_IN age_NN ,_, treatment_NN status_NN ,_, tumor_NN
          size_NN ,_, stage_NN ,_, and_CC HPV_NNP type_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD (_( GN_NNP )_) performed_VBN cell_NN culture_NN ,_, MSP_NNP and_CC gene_NN
        expression_NN analysis_NN ._. Author_NN 2_CD (_( HAP_NNP )_) participated_VBD in_IN the_DT
        collection_NN of_IN tumors_NNS ,_, clinical_JJ follow-up_JJ data_NNS ,_, and_CC
        performed_VBD HPV_NNP typing_VBG ._. Author_NN 3_CD (_( SK_NNP )_) participated_VBD in_IN MSP_NNP and_CC
        MSI_NNP analyses_NNS ._. Author_NN 4_CD (_( HV_NNP )_) participated_VBD in_IN collection_NN of_IN
        tumor_NN material_NN and_CC clinical_JJ information_NN ._. Author_NN 5_CD (_( FFZ_NNP )_)
        participated_VBD in_IN statistical_JJ analysis_NN ._. Author_NN 6_CD (_( JV_NNP )_)
        participated_VBD in_IN collection_NN of_IN normal_JJ cervical_JJ specimens_NNS ._.
        Author_NN 7_CD (_( AS_NNP )_) participated_VBD in_IN collection_NN of_IN cervical_JJ cancer_NN
        specimens_NNS and_CC clinical_JJ information_NN ._. Author_NN 8_CD (_( MBT_NNP )_)
        participated_VBD in_IN statistical_JJ analysis_NN and_CC interpretation_NN of_IN
        the_DT data_NNS ._. Author_NN 9_CD (_( MM_NNP )_) participated_VBD in_IN histologic_JJ
        diagnosis_NN and_CC immuno-histochemical_JJ analysis_NN ._. Author_NN 10_CD
        (_( VVM_NNP )_) has_VBZ conceived_VBN and_CC coordinated_VBN the_DT study_NN ._. All_DT authors_NNS
        read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
